Introduction: The HIV pandemic of 10-15 years ago spurred significant excitement and activity in the development of novel antifungal products to meet the sudden increase in patient potential. Newly launched products will expand the market, but face the challenge of increasing generic competition.
Scope: * Detailed description of the most significant systemic fungal infections
* Summary of the key risk factors associated with contracting invasive disease and US patient potential
* Historic sales data from 1997-2002 for key systemic fungal products
* Analysis of current products on the market, including a comparison of the activity spectrum and approved indications of these products
* Comprehensive analysis of late-stage R&D products, with Datamonitor forecasts of drug revenues to 2010
Report Highlights: The high level of clinical unmet need within the antifungals market will push physicians to continue switching from older, lower priced therapies to higher priced novel products, thereby driving growth in this market
Waning interest in drug R&D has led to a lack of products in mid-stage development. This has limited opportunity for antifungal companies with aging portfolios to in-license novel products
Reasons to Purchase: * Enhance sales forecasting and product positioning for the antifungals market through identification of treatment trends and key competition
* Optimize your understanding of the unmet need in the antifungals drug market and the strategies manufacturers are adopting to meet demand
* Identify areas of the antifungals market that are currently underserved by competitors (e.g. problematic pathogens, specific hospital settings)
* Identify target pathogens and high risk patient groups for drug development and optimal commercialization strategies
